Scale effect in bioequivalence evaluations

Area of Science:

• Pharmacokinetics and Drug Development
• Statistical Analysis in Clinical Trials
• Bioequivalence Study Design

Background:

• Bioequivalence evaluations are crucial for generic drug approval.
• Understanding factors influencing the ratio of sample means is essential for accurate assessments.
• Dosage strength and sampling variability can impact bioequivalence outcomes.

Purpose of the Study:

• To investigate the relationship between the magnitude of sample means and the test-reference ratio in bioequivalence.
• To analyze the scale effect of dosage strength on bioavailability measures.
• To quantify the impact of correlated sampling deviation on the test-reference ratio.

Main Methods:

• Utilized crossover trial data for test and reference drug products.
• Modeled the true test-reference ratio as a function of dosage strength and dose-response relationships.
• Employed deterministic simulation to assess the scale effect of correlated sampling deviation.

Main Results:

• Dosage strength, dose-response relationships, and correlated sampling deviation are key factors influencing sample means.
• Increasing dosage strength generally improves true test-reference ratios, albeit at a decreasing rate.
• Correlated sampling deviation significantly alters test-reference ratios, particularly for drugs with low bioavailability.

Conclusions:

• For extended-release products, focus development on the lowest strength if formulation-by-dose interaction is minimal.
• Conduct pilot studies for both highest and lowest strengths to detect formulation-by-dose interactions.
• Reference drug product mean magnitudes can signal systematic variations; consider repeating trials if means are unexpectedly low.